选择性四模式保膀胱治疗:诱导放化疗联合巩固性部分膀胱切除及盆腔淋巴结清扫治疗肌层浸润性膀胱癌的肿瘤学与功能结局:107例患者分析
本研究前瞻性纳入154例非转移性肌层浸润性膀胱癌(MIBC)患者,接受最大程度经尿道膀胱肿瘤电切术(TURBT)和诱导放化疗(CRT)后,完全缓解者接受巩固性部分膀胱切除术(PC)及盆腔淋巴结清扫(PLND)。121例(79%)达到完全缓解,107例(69%)完成四模式保膀胱方案;中位随访48个月,5年MIBC无复发生存率、癌症特异性生存率和总生存率分别为97%、93%和91%。
要点
- 107例完成四模式保膀胱方案的患者5年MIBC无复发生存率为97%。
- 完成方案者5年癌症特异性生存率和总生存率分别为93%和91%。
- 保留膀胱功能良好,SF-36各量表评分与年龄匹配参考值相当。
核心结论
- 选择性四模式保膀胱治疗联合巩固性PC及PLND在MIBC患者中取得良好的肿瘤学和功能结局。
- 巩固性PC可能有助于降低按此方案治疗患者的MIBC复发率。
研究设计与样本
- 前瞻性纳入154例非转移性MIBC患者,接受四模式保膀胱方案。
- 方案包括最大程度TURBT、诱导CRT,完全缓解者接受巩固性PC及PLND。
- 利用PC标本评估诱导CRT的病理缓解情况。
- 评估终点包括MIBC无复发生存率、癌症特异性生存率、总生存率及保留膀胱功能和生活质量。
主要发现
- 中位随访48个月。
- 诱导CRT后121例(79%)达到完全MIBC缓解,107例(69%)完成四模式保膀胱方案。
- 107例完成方案者中,病理检查发现11例(10%)存在残留浸润性癌(≥pT1)并手术切除,2例(2%)存在淋巴结转移。
- 107例完成方案者5年MIBC无复发生存率、癌症特异性生存率和总生存率分别为97%、93%和91%。
- 保留膀胱功能方面,中位最大排尿量350 mL、残余尿量25 mL、夜尿次数2次;SF-36各量表评分与年龄匹配参考值相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the oncological and functional outcomes associated with selective tetramodal bladder-sparing therapy, comprising maximal transurethral resection of bladder tumour (TURBT), induction chemoradiotherapy (CRT), and consolidative partial cystectomy (PC) with pelvic lymph node dissection (PLND). MATERIALS AND METHODS: In the present study, 154 patients with non-metastatic muscle-invasive bladder cancer (MIBC), prospectively enrolled in the tetramodal bladder-preservation protocol, were analysed. After TURBT and induction CRT, patients showing complete remission were offered consolidative PC with PLND for the achievement of bladder preservation. Pathological response to induction CRT was evaluated using PC specimens. Oncological and functional outcomes after bladder preservation were evaluated using the following endpoints: MIBC-recurrence-free survival (RFS); cancer-specific survival (CSS); overall survival (OS), and cross-sectional assessments of preserved bladder function and quality of life (QoL) including uroflowmetry, bladder diary, International Prostate Symptom Score, Overactive Bladder Symptom Score and the 36-item Short-Form Health Survey (SF-36) score. RESULTS: The median follow-up period was 48 months. Complete MIBC remission was achieved in 121 patients (79%) after CRT, and 107 patients (69%) completed the tetramodal bladder-preservation protocol comprising consolidative PC with PLND. Pathological examination in these 107 patients revealed residual invasive cancer (≥pT1) that was surgically removed in 11 patients (10%) and lymph node metastases in two patients (2%). The 5-year MIBC-RFS, CSS and OS rates in the 107 patients who completed the protocol were 97%, 93% and 91%, respectively. As for preserved bladder function, the median maximum voided volume, post-void residual urine volume, and nighttime frequency were 350 mL, 25 mL, and two voids, respectively. In the SF-36, patients had favourable scores, equivalent to the age-matched references in all the QoL scales. CONCLUSION: Selective tetramodal bladder-preservation therapy, incorporating consolidative PC with PLND, yielded favourable oncological and functional outcomes in patients with MIBC. Consolidative PC may have contributed to the low rate of MIBC recurrence in patients treated according to this protocol.
引用
- Kijima T, Tanaka H, Koga F, et al. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU Int. 2019. PMID: 30811784. doi:10.1111/bju.14736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。